[go: up one dir, main page]

UY26474A1 - Inhibidores de aminotransferasa dependiente de aminoácidos de cadena ramificada, y su uso en el tratamiento de la retinopatía diabética. - Google Patents

Inhibidores de aminotransferasa dependiente de aminoácidos de cadena ramificada, y su uso en el tratamiento de la retinopatía diabética.

Info

Publication number
UY26474A1
UY26474A1 UY26474A UY26474A UY26474A1 UY 26474 A1 UY26474 A1 UY 26474A1 UY 26474 A UY26474 A UY 26474A UY 26474 A UY26474 A UY 26474A UY 26474 A1 UY26474 A1 UY 26474A1
Authority
UY
Uruguay
Prior art keywords
amino acid
diabetic retinopathy
treatment
branched chain
amino acids
Prior art date
Application number
UY26474A
Other languages
English (en)
Inventor
Bryans Justin Stephen
Hu Lain-Yen
Susan M Hutson
Lanoue Kathryn Foley
Lieth Erich
Rafferty Michael Francis
Ryder Todd Robert
Su Ti-Zhi
Welty Devin Franklin
Wustrow David Juergen
Original Assignee
Warner Lambert Co
Penn State Res Found
Univ Wake Forest
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co, Penn State Res Found, Univ Wake Forest filed Critical Warner Lambert Co
Publication of UY26474A1 publication Critical patent/UY26474A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/11—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un método para el tratamiento profiláctico y terapéutico de la retinopatía diabética. El método consiste en la administración de un inhibidor de la vía de la aminotransferasa dependiente de aminoácidos de cadena ramificada (BCAT), a un animal, tal como un mamífero, en particular un humano, en una cantidad suficiente para tratar profiláctica o terapéuticamente la retinopatía diabética. La presente invención también se refiere a varios inhidores novedosos de la vía de la BCAT.
UY26474A 1999-12-08 2000-12-07 Inhibidores de aminotransferasa dependiente de aminoácidos de cadena ramificada, y su uso en el tratamiento de la retinopatía diabética. UY26474A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16963599P 1999-12-08 1999-12-08
US17539900P 2000-01-11 2000-01-11
US23002000P 2000-09-05 2000-09-05

Publications (1)

Publication Number Publication Date
UY26474A1 true UY26474A1 (es) 2001-01-31

Family

ID=27389690

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26474A UY26474A1 (es) 1999-12-08 2000-12-07 Inhibidores de aminotransferasa dependiente de aminoácidos de cadena ramificada, y su uso en el tratamiento de la retinopatía diabética.

Country Status (33)

Country Link
EP (1) EP1157000B1 (es)
JP (1) JP2003516379A (es)
KR (1) KR20010101811A (es)
CN (2) CN1170811C (es)
AP (1) AP2001002242A0 (es)
AR (1) AR037738A1 (es)
AT (1) ATE308510T1 (es)
AU (1) AU784553B2 (es)
BG (1) BG105875A (es)
BR (1) BR0008443A (es)
CA (1) CA2361647A1 (es)
CO (1) CO5280055A1 (es)
CZ (1) CZ20012758A3 (es)
DE (1) DE60023657T2 (es)
DZ (1) DZ3141A1 (es)
EA (1) EA006597B1 (es)
EE (1) EE200100416A (es)
ES (1) ES2252075T3 (es)
GE (1) GEP20043298B (es)
HK (1) HK1044933B (es)
HR (1) HRP20010581A2 (es)
HU (1) HUP0200570A3 (es)
IS (1) IS6033A (es)
MA (1) MA26777A1 (es)
MX (1) MXPA01008085A (es)
NO (1) NO20013844L (es)
OA (1) OA11759A (es)
PE (1) PE20010929A1 (es)
PL (1) PL349193A1 (es)
SK (1) SK11022001A3 (es)
UY (1) UY26474A1 (es)
WO (1) WO2001042191A1 (es)
YU (1) YU57401A (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
ATE540678T1 (de) 2001-06-11 2012-01-15 Xenoport Inc Prodrugs aus gaba-analoga, zusammensetzungen und ihre verwendungen
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
MXPA02010231A (es) 2001-11-27 2004-12-13 Warner Lambert Co Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
MXPA02010430A (es) * 2001-11-27 2003-06-02 Warner Lambert Co Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
DE602004010135T2 (de) * 2004-09-20 2008-09-04 Kao Corp. Verfahren zur Herstellung von Lactonen und deren Verwendung als Geruchsstoffe
RU2440112C2 (ru) 2004-11-04 2012-01-20 Ксенопорт, Инк. Пероральная дозированная форма габапентина замедленного высвобождения
US8828665B2 (en) 2007-02-16 2014-09-09 Ark Diagnostics, Inc. Compounds and methods for use in detecting gabapentin
WO2008155619A2 (en) * 2007-06-21 2008-12-24 Pfizer Inc. Preparation of optically-active cyclic amino acids
EP2349335B1 (en) 2008-10-24 2013-08-07 ARK Diagnostics, Inc. Levetiracetam immunoassays
EP2383255A1 (en) 2010-04-28 2011-11-02 Lacer, S.A. New compounds, synthesis and use thereof in the treatment of pain
EP2481801A1 (en) * 2011-01-28 2012-08-01 Deutsches Krebsforschungszentrum Inhibitors of branched-chain-aminotransferase-1 (BCAT1) for the treatment of neoplasia
EP2717869B1 (en) * 2011-06-13 2019-02-27 Ergon Pharmaceuticals LLC Methods of treatment using a bcat1 inhibitor
US10941109B2 (en) 2011-06-13 2021-03-09 Ergon Pharmaceuticals Llc Compositions and methods of treatment using a BCAT1 inhibitor
CN111635937B (zh) * 2020-06-29 2021-10-08 江苏省中医院 Ass1或bckdk抑制剂在制备治疗溃疡性结肠炎的药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE9800309A (et) * 1996-03-14 1999-02-15 Warner-Lambert Company Uued asendatud tsüklilised aminohapped kui farmatseutilised toimeained

Also Published As

Publication number Publication date
HUP0200570A3 (en) 2003-02-28
HUP0200570A2 (en) 2002-06-29
ATE308510T1 (de) 2005-11-15
IS6033A (is) 2001-07-31
MXPA01008085A (es) 2002-04-24
DE60023657T2 (de) 2006-07-20
DZ3141A1 (fr) 2001-01-14
AP2001002242A0 (en) 2001-09-30
EE200100416A (et) 2002-12-16
NO20013844D0 (no) 2001-08-07
EA200100791A1 (ru) 2002-04-25
NO20013844L (no) 2001-10-04
CA2361647A1 (en) 2001-06-14
HK1044933B (zh) 2005-06-03
CN1626069A (zh) 2005-06-15
MA26777A1 (fr) 2004-12-20
AU784553B2 (en) 2006-05-04
YU57401A (sh) 2004-05-12
AU1477901A (en) 2001-06-18
GEP20043298B (en) 2004-03-10
CN1170811C (zh) 2004-10-13
EP1157000A1 (en) 2001-11-28
PL349193A1 (en) 2002-07-01
AR037738A1 (es) 2004-12-01
EA006597B1 (ru) 2006-02-24
JP2003516379A (ja) 2003-05-13
CN1344245A (zh) 2002-04-10
ES2252075T3 (es) 2006-05-16
HK1044933A1 (en) 2002-11-08
HRP20010581A2 (en) 2002-08-31
BR0008443A (pt) 2001-10-30
WO2001042191A1 (en) 2001-06-14
BG105875A (en) 2002-05-31
PE20010929A1 (es) 2001-09-08
OA11759A (en) 2005-07-19
CZ20012758A3 (cs) 2002-09-11
CO5280055A1 (es) 2003-05-30
KR20010101811A (ko) 2001-11-14
SK11022001A3 (sk) 2002-11-06
EP1157000B1 (en) 2005-11-02
DE60023657D1 (de) 2005-12-08

Similar Documents

Publication Publication Date Title
UY26474A1 (es) Inhibidores de aminotransferasa dependiente de aminoácidos de cadena ramificada, y su uso en el tratamiento de la retinopatía diabética.
ATE461698T1 (de) Gaba-analoga zur verhütung und behandlung gastrointestinaler beschwerden
IS4576A (is) Lyfjasamsetning sem inniheldur prótónudælulata
DK1317419T3 (da) Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler
PT1196414E (pt) Pro-farmacos de inibidores carbamato de impdh
EA200200990A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы дельта человека
YU54401A (sh) Primena derivata 4-h-1-benzopiran-4-ona kao inhibitora preteranog razmnožavanja ćelija glatkih mišića
BG105754A (en) Pharmaceutical composition containing proton pump inhibitors
SG146643A1 (en) Treating or preventing restless legs syndrome using prodrugs of gaba analogs
NO20023464L (no) Sammensetning for intestinal avlevering
SI1677806T1 (sl) Postopki za zdravljenje akutnega in s preobremenitvijo povzročenega zvina in natega z uporabo hialuronske kisline
SE0202886D0 (sv) Dermatological use and a dermatological preparation
MXPA04011835A (es) Tratamiento de combinacion para la depresion y ansiedad.
IS5239A (is) Notkun á hliðstæðum gamma-amínósmjörsýru (GABA) áborð við GABA-pentín til vinnslu lyfs til meðferðar á bólgusjúkdómum
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
DK1220678T3 (da) Farmaceutiske præparater indeholdende kobber, salicylsyre og C-vitamin
ECSP003814A (es) Inhibidores de aminotransferasa dependiente de aminoacidos de cadena ramificada y su uso en el tratamiento de la retinopatia diabetica.
NO20052960L (no) Anvendelse av dokosahekasensyre som aktivt stoff til behandling av lipodystrofi
WO2001055108A3 (en) Use of spl a2 inhibitors for the treatment of inflammation
NO982854D0 (no) Nitrogenoksyd (NO) syntetase-inhibitor for Õ behandle eller forebygge type II diabetes
RU2004111209A (ru) Способ лечения эндометритов после родов
PL369845A1 (en) Use of 4-oxobutanoic acid derivatives in the treatment of inflammation
WO2004035030A3 (en) Combinations of benzodithiazoles and cox-2 inhibitors for the treatment of pain
BRPI0403271A (pt) composição de liberação in vivo
UA39384A (uk) Спосіб профілактики жовчнокам'яної хвороби

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20120529